Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
February 27, 2019 4:05 PM ESTRNA Franchise Advances-Reported EXONDYS 51® (eteplirsen) net sales of $84.4M for the quarter and full-year net sales of $301.0M, in line with guidance--Filed NDA for golodirsen with priority review, PDUFA August 19th-
Gene Therapy Engine Advances-Presented positive preliminary clinical data from the Limb-girdle muscular dystrophy (LGMD) Type 2E program, MYO-101, 51% beta-sarcoglycan gene expression, exceeding the threshold of 20% of beta-SG positive fiber expression above baseline in patients dosed at 5E13vg/kg--Exercised Option to Acquire Myonexus Therapeutics, including rights to Limb-girdle muscular dystrophy (LGMD) portfolio of five programs--Enhanced hybrid gene therapy manufacturing... More
